Dr. Hanna K. Sanoff
Claim this profileUNC Lineberger Comprehensive Cancer Center
Studies Colorectal Cancer
Studies Colon Cancer
10 reported clinical trials
21 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
dMMR positive
2Colon Cancer
Stage IV
Stage III
KRAS negative
Affiliated Hospitals
Clinical Trials Hanna K. Sanoff is currently running
FOLFIRINOX
for Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning. Chemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery. Researchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell. Depending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.
Recruiting1 award Phase 212 criteria
Chemotherapy Tailored by ctDNA Status
for Colon Cancer
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting1 award Phase 2 & 3
More about Hanna K. Sanoff
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Hanna K. Sanoff has experience with
- Oxaliplatin
- Bevacizumab
- Leucovorin
- Fluorouracil
- Irinotecan Hydrochloride
- Atezolizumab
Breakdown of trials Hanna K. Sanoff has run
Colorectal Cancer
Colon Cancer
Stomach Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hanna K. Sanoff specialize in?
Hanna K. Sanoff focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Hanna K. Sanoff currently recruiting for clinical trials?
Yes, Hanna K. Sanoff is currently recruiting for 3 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Hanna K. Sanoff has studied deeply?
Yes, Hanna K. Sanoff has studied treatments such as Oxaliplatin, Bevacizumab, Leucovorin.
What is the best way to schedule an appointment with Hanna K. Sanoff?
Apply for one of the trials that Hanna K. Sanoff is conducting.
What is the office address of Hanna K. Sanoff?
The office of Hanna K. Sanoff is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.